In early 2022, small-cap biotech Bluebird Bio (NASDAQ: BLUE) had no products on the market and was facing severe financial troubles. A lot has changed since then for the company. It now has two approved gene-editing therapies commercialized in the U.S. and has started to generate some revenue from them.

But that has done little for Bluebird's stock performance. The company has underperformed the broader market since then. Can Bluebird turn things around? Let's see how things could evolve for the gene-editing specialist in the next 12 months and decide whether its shares are worth buying.

Continue reading

Source Fool.com